Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cancer experimental bone metastasis in mouse models

Makoto Toneri, Shinji Miwa, Yong Zhang, Cameron Hu, Shuuya Yano, Yasunori Matsumoto, Michael Bouvet, Hayao Nakanishi, Robert M. Hoffman, Ming Zhao

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Bone metastasis is a frequent occurrence in prostate cancer patients and often is lethal. Zoledronic acid (ZOL) is often used for bone metastasis with limited efficacy. More effective models and treatment methods are required to improve the outcome of prostate cancer patients. In the present study, the effects of tumor-targeting Salmonella typhimurium A1-R were analyzed in vitro and in vivo on prostate cancer cells and experimental bone metastasis. Both ZOL and S. typhimurium A1-R inhibited the growth of PC-3 cells expressing red fluorescent protien in vitro. To investigate the efficacy of S. typhimurium A1-R on prostate cancer experimental bone metastasis, we established models of both early and advanced stage bone metastasis. The mice were treated with ZOL, S. typhimurium A1-R, and combination therapy of both ZOL and S. typhimurium A1-R. ZOL and S. typhimurium A1-R inhibited the growth of solitary bone metastases. S. typhimurium A1-R treatment significantly decreased bone metastasis and delayed the appearance of PC-3 bone metastases of multiple mouse models. Additionally, S. typhimurium A1-R treatment significantly improved the overall survival of the mice with multiple bone metastases. The results of the present study indicate that S. typhimurium A1-R is useful to prevent and inhibit prostate cancer bone metastasis and has potential for future clinical use in the adjuvant setting.

Original languageEnglish
Pages (from-to)31335-31343
Number of pages9
JournalOncotarget
Volume6
Issue number31
DOIs
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Bone Neoplasms
zoledronic acid
Salmonella typhimurium
Prostatic Neoplasms
Neoplasm Metastasis
Bone and Bones
Neoplasms
Bone Development
Therapeutics

Keywords

  • Bacterial therapy
  • Bone metastasis
  • GFP/RFP
  • Prostate cancer
  • Zoledronic acid

ASJC Scopus subject areas

  • Oncology

Cite this

Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cancer experimental bone metastasis in mouse models. / Toneri, Makoto; Miwa, Shinji; Zhang, Yong; Hu, Cameron; Yano, Shuuya; Matsumoto, Yasunori; Bouvet, Michael; Nakanishi, Hayao; Hoffman, Robert M.; Zhao, Ming.

In: Oncotarget, Vol. 6, No. 31, 01.01.2015, p. 31335-31343.

Research output: Contribution to journalArticle

Toneri, M, Miwa, S, Zhang, Y, Hu, C, Yano, S, Matsumoto, Y, Bouvet, M, Nakanishi, H, Hoffman, RM & Zhao, M 2015, 'Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cancer experimental bone metastasis in mouse models', Oncotarget, vol. 6, no. 31, pp. 31335-31343. https://doi.org/10.18632/oncotarget.5866
Toneri, Makoto ; Miwa, Shinji ; Zhang, Yong ; Hu, Cameron ; Yano, Shuuya ; Matsumoto, Yasunori ; Bouvet, Michael ; Nakanishi, Hayao ; Hoffman, Robert M. ; Zhao, Ming. / Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cancer experimental bone metastasis in mouse models. In: Oncotarget. 2015 ; Vol. 6, No. 31. pp. 31335-31343.
@article{09e1b30a929a43f88eb442b5fc0bf4af,
title = "Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cancer experimental bone metastasis in mouse models",
abstract = "Bone metastasis is a frequent occurrence in prostate cancer patients and often is lethal. Zoledronic acid (ZOL) is often used for bone metastasis with limited efficacy. More effective models and treatment methods are required to improve the outcome of prostate cancer patients. In the present study, the effects of tumor-targeting Salmonella typhimurium A1-R were analyzed in vitro and in vivo on prostate cancer cells and experimental bone metastasis. Both ZOL and S. typhimurium A1-R inhibited the growth of PC-3 cells expressing red fluorescent protien in vitro. To investigate the efficacy of S. typhimurium A1-R on prostate cancer experimental bone metastasis, we established models of both early and advanced stage bone metastasis. The mice were treated with ZOL, S. typhimurium A1-R, and combination therapy of both ZOL and S. typhimurium A1-R. ZOL and S. typhimurium A1-R inhibited the growth of solitary bone metastases. S. typhimurium A1-R treatment significantly decreased bone metastasis and delayed the appearance of PC-3 bone metastases of multiple mouse models. Additionally, S. typhimurium A1-R treatment significantly improved the overall survival of the mice with multiple bone metastases. The results of the present study indicate that S. typhimurium A1-R is useful to prevent and inhibit prostate cancer bone metastasis and has potential for future clinical use in the adjuvant setting.",
keywords = "Bacterial therapy, Bone metastasis, GFP/RFP, Prostate cancer, Zoledronic acid",
author = "Makoto Toneri and Shinji Miwa and Yong Zhang and Cameron Hu and Shuuya Yano and Yasunori Matsumoto and Michael Bouvet and Hayao Nakanishi and Hoffman, {Robert M.} and Ming Zhao",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.5866",
language = "English",
volume = "6",
pages = "31335--31343",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "31",

}

TY - JOUR

T1 - Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cancer experimental bone metastasis in mouse models

AU - Toneri, Makoto

AU - Miwa, Shinji

AU - Zhang, Yong

AU - Hu, Cameron

AU - Yano, Shuuya

AU - Matsumoto, Yasunori

AU - Bouvet, Michael

AU - Nakanishi, Hayao

AU - Hoffman, Robert M.

AU - Zhao, Ming

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Bone metastasis is a frequent occurrence in prostate cancer patients and often is lethal. Zoledronic acid (ZOL) is often used for bone metastasis with limited efficacy. More effective models and treatment methods are required to improve the outcome of prostate cancer patients. In the present study, the effects of tumor-targeting Salmonella typhimurium A1-R were analyzed in vitro and in vivo on prostate cancer cells and experimental bone metastasis. Both ZOL and S. typhimurium A1-R inhibited the growth of PC-3 cells expressing red fluorescent protien in vitro. To investigate the efficacy of S. typhimurium A1-R on prostate cancer experimental bone metastasis, we established models of both early and advanced stage bone metastasis. The mice were treated with ZOL, S. typhimurium A1-R, and combination therapy of both ZOL and S. typhimurium A1-R. ZOL and S. typhimurium A1-R inhibited the growth of solitary bone metastases. S. typhimurium A1-R treatment significantly decreased bone metastasis and delayed the appearance of PC-3 bone metastases of multiple mouse models. Additionally, S. typhimurium A1-R treatment significantly improved the overall survival of the mice with multiple bone metastases. The results of the present study indicate that S. typhimurium A1-R is useful to prevent and inhibit prostate cancer bone metastasis and has potential for future clinical use in the adjuvant setting.

AB - Bone metastasis is a frequent occurrence in prostate cancer patients and often is lethal. Zoledronic acid (ZOL) is often used for bone metastasis with limited efficacy. More effective models and treatment methods are required to improve the outcome of prostate cancer patients. In the present study, the effects of tumor-targeting Salmonella typhimurium A1-R were analyzed in vitro and in vivo on prostate cancer cells and experimental bone metastasis. Both ZOL and S. typhimurium A1-R inhibited the growth of PC-3 cells expressing red fluorescent protien in vitro. To investigate the efficacy of S. typhimurium A1-R on prostate cancer experimental bone metastasis, we established models of both early and advanced stage bone metastasis. The mice were treated with ZOL, S. typhimurium A1-R, and combination therapy of both ZOL and S. typhimurium A1-R. ZOL and S. typhimurium A1-R inhibited the growth of solitary bone metastases. S. typhimurium A1-R treatment significantly decreased bone metastasis and delayed the appearance of PC-3 bone metastases of multiple mouse models. Additionally, S. typhimurium A1-R treatment significantly improved the overall survival of the mice with multiple bone metastases. The results of the present study indicate that S. typhimurium A1-R is useful to prevent and inhibit prostate cancer bone metastasis and has potential for future clinical use in the adjuvant setting.

KW - Bacterial therapy

KW - Bone metastasis

KW - GFP/RFP

KW - Prostate cancer

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=84945548751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945548751&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5866

DO - 10.18632/oncotarget.5866

M3 - Article

VL - 6

SP - 31335

EP - 31343

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 31

ER -